Department of Biomedical Sciences, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
Med Oncol. 2023 Aug 7;40(9):264. doi: 10.1007/s12032-023-02138-y.
Cancer therapy has advanced from tradition chemotherapy methods to targeted therapy, novel drug delivery mechanisms, combination therapies etc. Although several novel chemotherapy strategies have been introduced, chemoresistance still remains as one of the major barriers in cancer treatments. Chemoresistance can lead to relapse and hinder the development of improved clinical results for cancer patients, and this continues to be the major hurdle in cancer therapy. Anticancer drugs acquire chemoresistance through different mechanisms. Understanding these mechanisms is crucial to overcome and increase the efficiency of the cancer therapies that are employed. The potential molecular pathways behind chemoresistance include tumor heterogeneity, elevated drug efflux, multidrug resistance, interconnected signaling pathways, and other factors. To surpass this limitation, new clinical tactics are to be introduced. This review aims to compile the most recent information on the molecular pathways that regulate chemoresistance in cancers, which will aid in development of new therapeutic targets and strategies.
癌症治疗已经从传统的化疗方法发展到靶向治疗、新型药物输送机制、联合治疗等。尽管已经引入了几种新的化疗策略,但仍然存在化疗耐药性,这是癌症治疗中的主要障碍之一。化疗耐药性会导致癌症复发,阻碍癌症患者临床疗效的改善,这仍然是癌症治疗中的主要障碍。抗癌药物通过不同的机制获得化疗耐药性。了解这些机制对于克服和提高所采用的癌症治疗的效率至关重要。化疗耐药性背后的潜在分子途径包括肿瘤异质性、药物外排增加、多药耐药性、相互关联的信号通路和其他因素。为了克服这一限制,需要引入新的临床策略。本综述旨在汇编调节癌症化疗耐药性的分子途径的最新信息,这将有助于开发新的治疗靶点和策略。